PVI
MDGL icon

Pura Vida Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pura Vida Investments’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,000
Closed -$10.4M – 133
2022
Q4 		$10.4M Buy
+36,000
New +$3.52M 0.54% 47

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pura Vida Investments's MDGL Position: Q4 2018 in Review

Pura Vida Investments sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 3,702 shares — an estimated $793K sold.

Pura Vida Investments first reported a position in MDGL in Q2 2018 and held it in 2 quarters. The position peaked at $3.66M in Q2 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Pura Vida Investments reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Pura Vida Investments sold 3,702 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $793K.
  • Pura Vida Investments first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Pura Vida Investments's Madrigal Pharmaceuticals position peaked at $3.66M in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Pura Vida Investments's 13F filing for Q4 2018, filed 14 Feb 2019.